Wuhan General Group (China), Inc.
Wuhan General Group (China), Inc.
Your view on WUHN
Overview
What the company does, where it operates, and who runs it.
About Wuhan General Group (China), Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Jeffrey Robinson
- Headquarters
- 6500 Transcanada hwy, Pointe-Claire, QC, CA
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Jeffrey Robinson
- Headquarters
- 6500 Transcanada hwy, Pointe-Claire, QC, CA
Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness.
The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Wuhan General Group (China), Inc., and the rating behind it. WUHN last traded at $0.0004; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Wuhan General Group (China), Inc.. Starting points for Wuhan General Group (China), Inc.: EPS -$0.03, beta -6.62 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Wuhan General Group (China), Inc.. Wuhan General Group (China), Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Wuhan General Group (China), Inc.. Trailing twelve-month EPS for Wuhan General Group (China), Inc. stands at -$0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Wuhan General Group (China), Inc.. Wuhan General Group (China), Inc. has reported as a listed company since 2006. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Wuhan General Group (China), Inc. valued side by side against its closest peers. Wuhan General Group (China), Inc. is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Wuhan General Group (China), Inc., and how their positions are changing. At a $22,060 market value, institutional positions materially move Wuhan General Group (China), Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Wuhan General Group (China), Inc. executives and directors. Shares of Wuhan General Group (China), Inc. have traded between $0.0001 and $0.0004 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Wuhan General Group (China), Inc.. Wuhan General Group (China), Inc. is a $22,060 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Wuhan General Group (China), Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Wuhan General Group (China), Inc.. Coverage tracks Wuhan General Group (China), Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.